Drug Type Monoclonal antibody |
Synonyms Dusigitumab (USAN), MEDI-573 |
Target |
Mechanism IGF-2 inhibitors(Insulin-like growth factor II inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10352 | Dusigitumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic breast cancer | Phase 2 | US | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | BE | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | CA | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | FR | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | DE | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | HU | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | IL | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | PL | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | ES | 13 Jun 2011 | |
Metastatic breast cancer | Phase 2 | BS | 13 Jun 2011 |
Phase 2 | 188 | Aromatase inhibitor+MEDI-573 (MEDI-573 30 mg/kg + AI) | twnxhbfopx(xzwiedsvnv) = fmtmhevycg zjzbmxlbdw (vvluhlpese, vcxcniyeau - udwynyxlsa) View more | - | 28 Aug 2018 | ||
Aromatase inhibitor+MEDI-573 (MEDI-573 45 mg/kg + AI) | twnxhbfopx(xzwiedsvnv) = prwyrlnmot zjzbmxlbdw (vvluhlpese, pyqcdesosu - fmjnkiingd) View more | ||||||
Phase 1 | 10 | fcjqmbsoca(gqebgotmwg) = fatigue (n = 2 patients), pyrexia (n = 2), diarrhoea (n = 2) and electrocardiogram QT prolongation (n = 2) ipmpmmorxr (ffpfqjeesg ) | Positive | 01 Feb 2015 |